Yahoo Finance13d
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025.
Positive Outlook for Abeona Therapeutics: FDA Acceptance and Strategic Initiatives Reinforce Buy Rating
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Abeona Therapeutics (ABEO – Research Report). The associated price ...
Daily14d
Pregabalin Significantly Reduces Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa: JAMA
Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...